MiNK Therapeutics
INKT
17 hedge funds and large institutions have $544K invested in MiNK Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 6 closing their positions.
1.38% more ownership
Funds ownership: 0.2% → 1.59% (+1.4%)
4% less capital invested
Capital invested by funds: $565K → $544K (-$20.7K)
19% less funds holding
Funds holding: 21 → 17 (-4)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.6K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$4.93K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.9K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$944 |
| 5 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$125 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$70.9K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$35.3K |
| 3 |
State Street
Boston,
Massachusetts
|
-$17.8K |
| 4 |
GWM
Greenwich Wealth Management
Greenwich,
Connecticut
|
-$8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$7.97K |
INKT Hedge Fund Activity: Q1 2025 in Review
17 institutional investors reported a position in MiNK Therapeutics (INKT) for Q1 2025, worth a combined $544K — down 3.7% from $565K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of INKT and 2 opened new positions — a net loss of 4 holders — while 10 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $14.6K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $70.9K sold.
- 17 institutional investors held MiNK Therapeutics (INKT) as of Q1 2025, down from 21 in Q4 2024.
- Funds reported $544K of MiNK Therapeutics stock for Q1 2025, down 3.7% quarter-over-quarter.
- 2 funds opened new MiNK Therapeutics positions in Q1 2025 and 6 closed out, a net change of -4 holders.
- The largest MiNK Therapeutics buyer in Q1 2025 was Geode Capital Management, an estimated $14.6K added.
- The largest MiNK Therapeutics seller in Q1 2025 was Renaissance Technologies, an estimated $70.9K sold.
Based on aggregated 13F filings for Q1 2025.